PharVision Advisers’s Curtiss-Wright CW Stock Holding History

PharVision Advisers’s Portfolio CW Stock Details CW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,230	Closed	-$390K	–	302
2025 Q1	$390K	Buy	+1,230	New	+$415K	0.54%	39

Other funds holding CW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

PharVision Advisers's CW Position: Q2 2025 in Review

PharVision Advisers sold out of Curtiss-Wright (CW) in Q2 2025, closing a stake of 1,230 shares — an estimated $390K sold.

PharVision Advisers first reported a position in CW in Q1 2025 and held it in 1 quarter. The position peaked at $390K in Q1 2025. 740 funds tracked by Wall St. Rank hold CW as of Q2 2025.

PharVision Advisers reported no remaining Curtiss-Wright position as of Q2 2025 after selling out during the quarter.
PharVision Advisers sold 1,230 Curtiss-Wright shares in Q2 2025, an estimated $390K.
PharVision Advisers first reported a position in Curtiss-Wright in Q1 2025 and held it in 1 quarter.
PharVision Advisers's Curtiss-Wright position peaked at $390K in Q1 2025.
740 funds tracked by Wall St. Rank held Curtiss-Wright as of Q2 2025.

Based on PharVision Advisers's 13F filing for Q2 2025, filed 13 Aug 2025.